# A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

> **NCT05243550** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **UroGen Pharma Ltd.** · enrollment: 240 (actual)

## Conditions studied

- Bladder Cancer
- Urothelial Carcinoma
- Urothelial Carcinoma Bladder

## Interventions

- **DRUG:** UGN-102

## Key facts

- **NCT ID:** NCT05243550
- **Lead sponsor:** UroGen Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-01
- **Primary completion:** 2023-04-26
- **Final completion:** 2028-03
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2026-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05243550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05243550, "A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT05243550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*